Identification of putative molecular imaging probes for BACE-1 by accounting for protein flexibility in virtual screening

Journal of Alzheimer's Disease

Volumn 29, Issue 2, 2012, Pages 351-359

  Lang, Haijing ^a   Huang, Xudong ^b,c   Yang, Yongliang ^a  

^a DALIAN UNIVERSITY OF TECHNOLOGY   (China)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Alzheimer's disease; BACE; MICAD; PET probes; protein flexibility; receptor ensemble; virtual screening

Indexed keywords

AMYLOID BETA PROTEIN; BETA SECRETASE 1; BROMINE 76; CARBON 11; CONTRAST MEDIUM; COPPER 64; FLUORINE 18; LIGAND;

ALZHEIMER DISEASE; ARTICLE; BINDING AFFINITY; DISEASE COURSE; EARLY DIAGNOSIS; HUMAN; MOLECULAR IMAGING; MOLECULAR PROBE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN DATA BANK; PROTEIN STRUCTURE; SCREENING; VIRTUAL REALITY;

EID: 84859417074     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2011-111787     Document Type: Article

References (26)

1. Cole SL, Vassar R (2007) The Alzheimer's disease fj-secretase enzyme, BACE1. Mol Neurodegener 2, 22.
2. Nordberg A, Rinne JO, Kadir A, Langstrom B (2010) The use of PET in Alzheimer disease. Nat Rev Neurol 6, 78-87.
3. Okamura N, Suemoto T, Shiomitsu T, Suzuki M, Shimadzu H, Akatsu H, Yamamoto T, Arai H, Sasaki H, Yanai K, Staufenbiel M, Kudo Y, Sawada T (2004) A novel imaging probe for in vivo detection of neuritic and diffuse amyloid plaques in the brain. J Mol Neurosci 24, 247-255. (Pubitemid 41359152)
4. 76Br-labeled sigma2-receptor ligands. J Nucl Med 47, 1041-1048. (Pubitemid 46939958)
5. Bajorath J (2002) Integration of virtual and high-throughput screening. Nat Rev Drug Discov 1, 882-894. (Pubitemid 37361583)
6. Kryger G, Silman I, Sussman JL (1999) Structure of acetylcholinesterase complexed with E2020 (Aricept): Implications for the design of new anti-Alzheimer drugs. Structure 7, 297-307. (Pubitemid 29159689)
7. Wlodawer A, Vondrasek J (1998) Inhibitors of HIV-1 protease: A major success of structure-assisted drug design. Annu Rev Biophys Biomol Struct 27, 249-284. (Pubitemid 28286016)
8. McInnes C (2007) Virtual screening strategies in drug discovery. Curr Opin Chem Biol 11, 494-502. (Pubitemid 47589008)
9. Lam PY, Jadhav PK, Eyermann CJ, Hodge CN, Ru Y, Bacheler LT, Meek JL, Otto MJ, Rayner MM, Wong YN (1994) Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors. Science 263, 380-384. (Pubitemid 24067944)
10. Teodoro ML, Kavraki LE (2003) Conformational flexibility models for the receptor in structure based drug design. Curr Pharm Des 9, 1635-1648. (Pubitemid 36966031)
11. Cavasotto CN, Abagyan RA (2004) Protein flexibility in lig-and docking and virtual screening to protein kinases. J Mol Biol 337, 209-225. (Pubitemid 38270258)
12. Frimurer TM, Peters GH, Iversen LF, Andersen HS (2003) Ligand-induced conformational changes: Improved predictions of ligand binding conformations and affinities. Biophys J 84, 2273-2281. (Pubitemid 36373550)
13. Damm KL, Carlson HA (2007) Exploring experimental sources of multiple protein conformations in structure-based drug design. J Am Chem Soc 129, 8225-8235. (Pubitemid 47039084)
14. Cheng LS, Amaro RE, Xu D, Li WW, Arzberger PW, McCammon JA (2008) Ensemble-based virtual screening reveals potential novel antiviral compounds for avian influenza neuraminidase. J Med Chem 51, 3878-3894. (Pubitemid 351956517)
15. Huey R, Morris GM, Olson AJ, Goodsell DS (2007) A semiempirical free energy force field with charge-based des-olvation. J Comput Chem 28, 1145-1152. (Pubitemid 46506716)
16. Russell RB, Barton GJ (1992) Multiple protein sequence alignment from tertiary structure comparison: Assignment of global and residue confidence levels. Proteins 14, 309-323.
17. Amaro RE, Baron R, McCammon JA (2008) An improved relaxed complex scheme for receptor flexibility in computer-aided drug design. J Comput Aided Mol Des 22, 693-705.
18. Rowland DJ, Tu Z, Xu J, Ponde D, Mach RH, Welch MJ (2006) Synthesis and in vivo evaluation of 2 high-affinity 76Br-labeled sigma2-receptor ligands. J Nucl Med 47, 1041-1048. (Pubitemid 46939958)
19. Kil KE, Ding YS, Lin KS, Alexoff D, Kim SW, Shea C, Xu Y, Muench L, Fowler JS (2007) Synthesis and positron emission tomography studies of carbon-11-labeled imatinib (Gleevec). Nucl Med Biol 3, 153-163.
20. Cai H, Fissekis J, Conti PS (2009) Synthesisof a novel bifunc-tional chelator AmBaSar based on sarcophagine for peptide conjugation and (64) Cu radiolabelling. Dalton Trans, 5395-5400.
21. Bettio A, Honer M, Müller C, Brühlmeier M, Müller U, Schibli R, Groehn V, Schubiger AP, Ametamey SM (2006) Synthesis and preclinical evaluation of a folic acid derivative labeled with 18F for PET imaging of folate receptor-positive tumors. J Nucl Med 47, 1153-1160. (Pubitemid 47544910)
22. Totrov M, Abagyan R (2008) Flexible liganddocking to multiple receptor conformations:Apractical alternative. Curr Opin Struct Biol 18, 178-184.
23. Durrant JD, McCammon JA (2010) Computer-aided drug-discovery techniques that accountfor receptorflexibility.Curr Opin Pharmacol 10, 770-774.
24. Teodoro ML, Kavraki LE (2003) Conformational flexibility models for the receptor in structure based drug design. Curr Pharm Des 9, 1635-1648. (Pubitemid 36966031)
25. O'Donoghue P, Luthey-Schulten Z (2005) Evolutionary profiles derived from the QR factorization of multiple structural alignments gives an economy of information. J Mol Biol 346, 875-894. (Pubitemid 40247724)
26. Yang T, Wu JC, Yan C, Wang Y, Luo R, Gonzales MB, Dalby KN, Ren P (2011) Virtual screening using molecular simulations. Proteins 79, 1940-1951.